Cited by 66ECG Monitoring and AnalysisArtificial Intelligence in HealthcareArtificial Intelligence in Healthcare and Education

Artificial Intelligence-Augmented Electrocardiogram Detection of Left Ventricular Systolic Dysfunction in the General Population

Open access
Kashou, Anthony H., Medina-Inojosa, Jose R., Noseworthy, Peter A., Rodeheffer, Richard J., Lopez-Jimenez, Francisco, Attia, Itzhak Zachi, Kapa, Suraj, Scott, Christopher G. +3 more·2021·Mayo Clinic Proceedings

Abstract

Objective To validate an artificial intelligence-augmented electrocardiogram (AI-ECG) algorithm for the detection of preclinical left ventricular systolic dysfunction (LVSD) in a large community-based cohort. Methods We identified a randomly selected community-based cohort of 2041 subjects age 45 years or older in Olmsted County, Minnesota. All participants underwent a study echocardiogram and ECG. We first assessed the performance of the AI-ECG to identify LVSD (ejection fraction ≤40%). After excluding participants with clinical heart failure, we further assessed the AI-ECG to detect preclinical LVSD among all patients (n=1996) and in a high-risk subgroup (n=1348). Next we modelled an imputed screening program for preclinical LVSD detection where a positive AI-ECG triggered an echocardiogram. Finally, we assessed the ability of the AI-ECG to predict future LVSD. Participants were enrolled between January 1, 1997, and September 30, 2000; and LVSD surveillance was performed for 10 years after enrollment. Results For detection of LVSD in the total population (prevalence, 2.0%), the area under the receiver operating curve for AI-ECG was 0.97 (sensitivity, 90%; specificity, 92%); in the high-risk subgroup (prevalence 2.7%), the area under the curve was 0.97 (sensitivity, 92%; specificity, 93%). In an imputed screening program, identification of one preclinical LSVD case would require 88.3 AI-ECGs and 8.7 echocardiograms in the total population and 65.7 AI-ECGs and 5.5 echocardiograms in the high-risk subgroup. The unadjusted hazard ratio for a positive AI-ECG for incident LVSD over 10 years was 2.31 (95% CI, 1.32 to 4.05; P=.004). Conclusion Artificial intelligence-augmented ECG can identify preclinical LVSD in the community and warrants further study as a screening tool for preclinical LVSD.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.mayocp.2021.02.029

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • AI-ECG has a dual role: opportunistic screening in asymptomatic patients and evaluation of symptomatic patients in whom ventricular dysfunction is part of the differential.

    “Read together, these studies point to a dual role: opportunistic screening in asymptomatic patients, and evaluation of symptomatic patients in whom ventricular dysfunction is part of the differential.”

    From Deep Learning Applied to 12-Lead ECGs for Detection of Structural, Metabolic and Systemic Disease (2026) · cites this paper as [17]

    The Methods section models AI-ECG screening in a community population without heart-failure symptoms, and the Discussion describes its potential as a screening tool for preclinical LVSD. The paper does not establish the other proposed role—evaluating symptomatic patients when ventricular dysfunction is in the differential. Its Discussion mentions an earlier clinical ECG study, but does not identify that study’s patients as symptomatic or frame it around that diagnostic use. (LLM, conf=0.88)

    Experimental — accuracy not yet measured
  • AI-ECG has strong performance for detecting preclinical left ventricular systolic dysfunction in a community-based cohort.

    “Kashou et al. studied a community-based cohort and reported strong performance for detecting preclinical left ventricular systolic dysfunction, supporting the potential role of AI-ECG in upstream screening before overt heart failure is recognized [17].”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The citation lists haven’t been fetched yet

References 23 · Cited by 66

Research works printed but not linked: 22

  1. [1]Redfield MM, Jacobsen SJ, Burnett JC Jr, Mahoney DW, Bailey KR, Rodeheffer RJ. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA. 2003; 289: 194– 202. 12517230
  2. [3]Echouffo-Tcheugui JB, Erqou S, Butler J, Yancy CW, Fonarow GC. Assessing the risk of progression from asymptomatic left ventricular dysfunction to overt heart failure: a systematic overview and meta-analysis. JACC Heart Fail. 2016; 4: 237– 248. 26682794
  3. [4]Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC, Klein M, Lamas G, Packer M, Rouleau J, Rouleau JL, Rutherford J, Wetheime JH, Hawkin CM. Effect of captopril on mortality and morbidity in patients with left-ventricular dysfunction after myocardial-infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med. 1992; 327: 669– 677. 1386652
  4. [5]Davenport C, Cheng EY, Kwok YT, Lai AH, Wakabayashi T, Hyde C, Connock M. Assessing the diagnostic test accuracy of natriuretic peptides and ECG in the diagnosis of left ventricular systolic dysfunction: a systematic review and meta-analysis. Br J Gen Pract. 2006; 56: 48– 56. 16438815 PMC1821403
  5. [6]Atherton JJ. Screening for left ventricular systolic dysfunction: is imaging a solution? JACC Cardiovasc Imaging. 2010; 3: 421– 428. 20394904
  6. [7]Costello-Boerrigter LC, Boerrigter G, Redfield MM, Rodeheffer RJ, Urban LH, Mahoney DW, Jacobsen SJ, Heublein DM, Burnett JC Jr. Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in the general community: determinants and detection of left ventricular dysfunction. J Am Coll Cardiol. 2006; 47: 345– 353. 16412859 PMC2647136
  7. [8]Redfield MM, Rodeheffer RJ, Jacobsen SJ, Mahoney DW, Bailey KR, Burnett JC Jr. Plasma brain natriuretic peptide to detect preclinical ventricular systolic or diastolic dysfunction: a community-based study. Circulation. 2004; 109: 3176– 3181. 15184280
  8. [10]Attia ZI, Kapa S, Lopez-Jimenez F, McKie PM, Ladewig DJ, Satam G, Pellikka PA, Enriguez-Sarano M, Noseworthy PA, Munger TM, Asirvatham SJ, Scott CG, Carter RE, Friedman PA. Screening for cardiac contractile dysfunction using an artificial intelligence-enabled electrocardiogram. Nat Med. 2019; 25: 70– 74. 30617318
  9. [11]Melton LJ, 3rd. History of the Rochester Epidemiology Project. Mayo Clin Proc. 1996; 71: 266– 274. 8594285
  10. [13]Jacobsen SJ, Mahoney DW, Redfield MM, Bailey KR, Burnett JC Jr, Rodeheffer RJ. Participation bias in a population-based echocardiography study. Ann Epidemiol. 2004; 14: 579– 584. 15350958
  11. [14]McKie PM, Rodeheffer RJ, Cataliotti A, Martin FL, Urban LH, Mahoney DW, Jacobsen SJ, Redfield MM, Burnett JC Jr. Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide: biomarkers for mortality in a large community-based cohort free of heart failure. Hypertension. 2006; 47: 874– 880. 16585413 PMC2647805
  12. [15]McKee PA, Castelli WP, McNamara PM, Kannel WB. The natural history of congestive heart failure: the Framingham study. N Engl J Med. 1971; 285: 1441– 1446. 5122894
  13. [16]Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJ, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WH, Tsai EJ, Wilkoff BL. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013. 62: e147– 239. 23747642
  14. [17]McKie PM, Cataliotti A, Lahr BD, Martin FL, Redfield MM, Bailey KR, Rodeheffer RJ, Burnett JC Jr. The prognostic value of N-terminal pro-B-type natriuretic peptide for death and cardiovascular events in healthy normal and stage A/B heart failure subjects. J Am Coll Cardiol. 2010; 55: 2140– 2147. 20447539 PMC3770189
  15. [19]Roger VL, Weston SA, Redfield MM, Hellermann-Homan JP, Killian J, Yawn BP, Jacobsen SJ. Trends in heart failure incidence and survival in a community-based population. JAMA. 2004; 292: 344– 500. 15265849
  16. [20]Vasan RS, Benjamin EJ, Larson MG, Leip EP, Wang TJ, Wilson PW, Levy D. Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: the Framingham Heart Study. JAMA. 2002; 288: 1252– 1259. 12215132
  17. [21]Olesen LL, Andersen A. ECG as a first step in the detection of left ventricular systolic dysfunction in the elderly. ESC Heart Failure. 2016; 3: 44– 52. 27774266 PMC5061087
  18. [22]Ewald B, Ewald D, Thakkinstian A, Attia J. Meta-analysis of B type natriuretic peptide and N-terminal pro B natriuretic peptide in the diagnosis of clinical heart failure and population screening for left ventricular systolic dysfunction. Intern Med J. 2008; 38: 101– 113. 18290826
  19. [23]Latour-Perez J, Coves-Orts FJ, Abad-Terrado C, Abraira V, Zamora J. Accuracy of B-type natriuretic peptide levels in the diagnosis of left ventricular dysfunction and heart failure: a systematic review. Eur J Heart Fail. 2006l8: 390– 399. 16305826
  20. [24]Betti I, Castelli G, Barchielli A, Belgini C, Boscherini V, De Luca L, Messeri G, Gheorghiade M, Maisel A, Zuppiroli A. The role of N-terminal PRO-brain natriuretic peptide and echocardiography for screening asymptomatic left ventricular dysfunction in a population at high risk for heart failure. The PROBE-HF study. J Card Fail. 2009; 15: 377– 384. 19477397
  21. [25]Yasin OZ, Attia Z, Dillon JJ, DeSimone CV, Sapir Y, Dugan J, Somers VK, Ackerman MK, Asirvatham DJ, Scott CG, Bennet KE, Ladewig DJ, Sadot D, Geva AB, Friedman PA. Noninvasive blood potassium measurement using signal-processed, single-lead ecg acquired from a handheld smartphone. J Electrocardiol. 50: 620– 625. 28641860 PMC5652040
  22. [26]Attia ZI, Dugan J, Maidens J, Rideout A, Lopez-Jimenez F, Noseworthy PA, Asirvatham S, Pellikka PA, Ladewig DJ, Satam G, Pham S, Venkatraman S, Friedman P, Kapa S. Prospective Analysis of Utility of Signals From an Ecg-Enabled Stethoscope to Automatically Detect a Low Ejection Fraction Using Neural Network Techniques Trained From the Standard 12-Lead Ecg. 2019; 140:A13447.

Authors
Kashou, A. H., Medina-Inojosa, J. R., Noseworthy, P. A., Rodeheffer, R. J., Lopez-Jimenez, F., Attia, I. Z., Kapa, S., Scott, C. G., Lee, A. T., Friedman, P. A., & McKie, P. M.
Affiliations
Mayo Clinic (US)
Corresponding author
McKie, Paul M.
Venue
Mayo Clinic Proceedings
Publisher
Elsevier BV
Published
2021-10
Volume
96
Issue
10
Pages
2576-2586
ISSN
0025-6196 (ISSN-L)
OpenAlex
W3167842829
Cited by
66
References
23
Citations by year
2026: 23 · 2025: 19 · 2024: 11 · 2023: 5 · 2022: 7 · 2021: 1
FWCI
4.02
Type
journal article
Language
en
Open access
Locations
  • Mayo Clinic Proceedings (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
National Institutes of Health (R01-AG034676, NHLBI RO1-5502)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › ECG Monitoring and Analysis
  • Health Sciences › Health Professions › Health Information Management › Artificial Intelligence in Healthcare
  • Health Sciences › Medicine › Health Informatics › Artificial Intelligence in Healthcare and Education
Keywords
left ventricular systolic dysfunction, preclinical heart failure, heart failure screening, echocardiography, ejection fraction, vulnerable populations, community-based cohort
MeSH terms
Algorithms, Artificial Intelligence, Echocardiography, Electrocardiography, Female, Humans, Male, Middle Aged, Sensitivity and Specificity, Ventricular Function, Left, Ventricular Dysfunction, Left

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review